Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Teva Acting CEO Eyal Desheh: Teva Has 13 New Therapeutic Entities Waiting For Approval

Ratiopharm Purchased By Teva News Conference

Acting CEO Eyal Desheh / Getty

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) acting CEO Eyal Desheh today said that Copaxone continued to lead in new prescriptions for multiple sclerosis in the third quarter of 2013, despite competition in the market. In the conference call following the publication of Teva’s financial report, Desheh said that Copaxone continued to lead in new prescriptions for multiple sclerosis in the US. “Despite the competition, Copaxone leads in prescriptions and in new prescriptions, ” he said. Copaxone sales rose 1% in the third quarter to $1.05 billion.

Copaxone’s latest rival is Tecfidera, made by Biogen Idec Inc. (Nasdaq: BIIB), which had $280 million in sales in the third quarter, $50 million more than the analysts’ forecasts. Analysts have marked Tecfidera as a blockbuster, which will reach $3 billion in annual sales.

Commenting on Teva’s new therapeutic entities (NTE) program, on which the company is pinning its hopes, Desheh predicts that these generic drugs will have billions of dollars in annual sales with higher profit margins than regular generics.

On December 5, Teva will provide more details about its R&D program, with an emphasis on NTEs. Desheh said today that Teva already had 13 NTEs waiting for approval, meeting its target for this year.

Bank of America Merrill Lynch analyst Gregg Gilbert asked Teva president of Global R&D and CSO Dr. Michael Hayden if he would stay on, following Jeremy Levin’s firing. Hayden said yes. “I feel that it is a privilege to be the head of the R&D division. I am grateful to Dr. Levin. I will continue to fulfill my duties and realize the strategy, which I think is unique in the industry. My commitment has not changed.”

Published by  www.globes-online.com 

 

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News